Our Team

Dr Jason Clark

Chief Scientific Officer

Dr Clark is one of the world’s leading industrial phage scientists, and has spent over 10 years in phage companies. He has considerable experience of manufacturing phages to GMP standards.

Dr Clark holds a PhD in microbiology.

Athol P Haas

Chief Commercial Officer

Athol has worked in C-Suite positions in several industries including biotechnology, creative/digital, food + drink, weapons and defence and telecoms/IT. His diverse background brings a wealth of experience to the commercial and business development of Fixed Phage.

Dr Emma Bell

Principal Research Scientist

With over 12 years’ experience in bacteriophage science Emma is part of the team who originally developed Fixed Phage technology. Following her PhD in bacteriophage ecology Emma did two post-doctorate posts, one of which was for the development of the technology. Emma oversees the science projects within Fixed Phage and ensures customer objectives are fulfilled.

Dr Gordon Smith

Senior Laboratory Scientist

Primary research into novel bacteriophage immobilisation technology. Responsible for the design and implementation of quality systems, experimental design, project management, grant applications, reporting and communication with clients and liaison between shareholders and research staff.

John Carney

Chairman

John has over forty years’ experience of achieving long term value creation and realisation through building technology based enterprises in growth industries. Formerly, he was a Director of Corporate Finance with Hoare Govett in London.

Alec Mackie

Chief Financial Officer and Company Secretary

Alec acts as Finance Director and Company Secretary through Barwell Consulting Limited. Alec is Managing Director of Barwell Plc and has extensive experience of investing in start-ups and emerging technology companies with high growth potential.

Dr Mike Mattey

Founder and Member of the Scientific Advisory Board

World leading expert in phage research. Founder of Fixed Phage and Inventor of technology.

Dr Trevor Langley

Non-Executive Director and Member of the Scientific Advisory Board

An experienced manager, with an entrepreneurial flair, who has formed a number of start-up bioscience-based product and service companies from scratch. He enjoys the challenges of this environment, particularly working in teams with groups of like-minded individuals.

Jim Reid

Non- Executive Director

Jim is co-founder of ChimaeraBio which is a life science specialist investment fund investing on behalf of the Reid family. The fund is managed by Jim and Karen Reid and it has been involved with a number of Scotland’s more successful life science companies including Haptogen (acquired by Wyeth), Qnostics (acquired by BBI plc) and D3 Technologies (acquired by Renishaw plc).

Jim represents the interests of Scottish Investment Bank.